Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Otsuka Pharmaceutical Development & Commercialization, Inc.
With
Otsuka Pharmaceutical Co., Ltd.
Subjects will receive a dose of study medication and will undergo a PET scan at 4 hrs and 23.5 hours post dose. Subjects will remain in the clinic from Day-1 to Day 7 for PK sample collection and safety monitoring. Subjects will return to the clinic on Day 10 for a follow-up safety assessment.
Age
18–45
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Males and non-child bearing potential females between 18 and 45 years of age, inclusive.
BMI between 19 and 32 kg/m2, inclusive.
You may not be if
Condition or history which may present a safety concern to the subject or interfere with outcome variables.
History of or current drug or alcohol abuse, hepatitis, AIDS, or drug allergy.
Use of prescription, over-the-counter, or herbal medication, or vitamin supplements within 14 days or antibiotics within 30 days.
Use of tobacco products or daily exposue to second hand smoke.
Blood pressure higher than 140/90 mmHg or lower than 100/50 mmHg: heart rate outside 40 to 90 beats/minute.
History of serious mental disorder.
Clareo Health | Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712
